Tolerance & resistance to β2-agonist bronchodilators

Paediatric Respiratory Reviews

Volumn 14, Issue 3, 2013, Pages 195-198

  Yim, Robert P ^a   Koumbourlis, Anastassios C ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

2 agonists; Resistance; Tolerance

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FENOTEROL; PLACEBO; SALBUTAMOL; SALMETEROL;

ADRB2 GENE; AIRWAY OBSTRUCTION; AMINO ACID SUBSTITUTION; ASTHMA; BRONCHODILATING ACTIVITY; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; DOSAGE SCHEDULE COMPARISON; DRUG CHOICE; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; HUMAN; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

RESISTANCE; TOLERANCE; Β(2)-AGONISTS;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; ASTHMA; BRONCHOCONSTRICTION; BRONCHODILATOR AGENTS; DRUG RESISTANCE; DRUG TOLERANCE; HUMANS; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA-2;

EID: 84881544216     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2012.11.002     Document Type: Review

References (40)

1. Johnson M. The beta-adrenoceptor. American Journal of Respiratory and Critical Care Medicine 1998, 158(5 Pt 3):S146-S153.
2. Johnson M. Mechanisms of action of b-adrenoceptor agonists. In: Costello JFaM, R.D., editor. Beta-Agonists in the Treatment of Asthma. Parthenon: Carnforth; 1992. p. 27-42.
3. Broadley K.J. Beta-adrenoceptor responses of the airways: for better or worse?. European Journal of Pharmacology 2006, 533:15-27.
4. Carstairs J.R., Nimmo A.J., Barnes P.J. Autoradiographic visualization of beta-adrenoceptor subtypes in human lung. The American Review of Respiratory Disease 1985, 132(3):541-547.
5. Knox A.J., Tattersfield A.E. Airway smooth muscle relaxation. Thorax 1995, 50(8):894-901.
6. Weir T.D., Mallek N., Sandford A.J., Bai T.R., Awadh N., Fitzgerald J.M., et al. beta2-Adrenergic receptor haplotypes in mild, moderate and fatal/near fatal asthma. American Journal of Respiratory and Critical Care Medicine 1998, 158(3):787-791.
7. Johnson M. Beta2-adrenoceptors: mechanisms of action of beta2-agonists. Paediatric Respiratory Reviews 2001, 2(1):57-62.
8. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. The Journal of Allergy and Clinical Immunology. 2007; 120(5 Suppl):S94-138.
9. Johnson M. Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. The Journal of Allergy and Clinical Immunology 2006, 117:18-24.
10. Cockcroft D.W., Murdock K.Y. Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine. The Journal of Allergy and Clinical Immunology 1987, 79(5):734-740.
11. Grainger J., Woodman K., Pearce N., Crane J., Burgess C., Keane A., et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. Thorax 1991, 46:105-111.
12. Pearce N., Grainger J., Atkinson M., Crane J., Burgess C., Culling C., et al. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax 1990, 45(3):170-175.
13. Crane J., Pearce N., Flatt A., Burgess C., Jackson R., Kwong T., et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet 1989, 1:917-922.
14. Sears M.R., Taylor D.R., Print C.G., et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990, 336:1391-1396.
15. Spitzer W.O., Suissa S., Ernst P., Horwitz R.I., Habbick B., Cockcroft D., et al. The use of beta-agonists and the risk of death and near death from asthma. The New England Journal of Medicine 1992, 326:501-506.
16. Walters E.H., Walters J. Inhaled short acting beta2-agonist use in asthma: regular vs as needed treatment. Cochrane Database Syst Rev 2000, CD001285.
17. Inman M.D., O'Byrne P.M. The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. American Journal of Respiratory and Critical Care Medicine 1996, 153:65-69.
18. Sears M.R., Taylor D.R. The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology. Drug safety: an International Journal of Medical Toxicology and Drug Experience 1994, 11:259-283.
19. Cooper P.R., Panettieri R.A. Steroids completely reverse albuterol-induced beta(2)-adrenergic receptor tolerance in human small airways. The Journal of Allergy and Clinical Immunology 2008, 122(4):734-740.
20. Barnes P.J. Beta-adrenergic receptors and their regulation. American Journal of Respiratory and Critical Care Medicine 1995, 152(3):838-860.
21. Hadcock J.R., Wang H.Y., Malbon C.C. Agonist-induced destabilization of beta-adrenergic receptor mRNA. Attenuation of glucocorticoid-induced up-regulation of beta-adrenergic receptors. The Journal of Biological Chemistry 1989, 264:19928-19933.
22. Adkinson N.F., Middleton E. Middleton's allergy: principles & practice 2009, Mosby/Elsevier, Philadelphia, PA. 7th ed.
23. O'Connor B.J., Aikman S.L., Barnes P.J. Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma. The New England Journal of Medicine 1992, 327:1204-1208.
24. Boulet L.P., Chakir J., Milot J., Boutet M., Laviolette M. Effect of salmeterol on allergen-induced airway inflammation in mild allergic asthma. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 2001, 31:430-437.
25. Gauvreau G.M., Jordana M., Watson R.M., Cockroft D.W., O'Byrne P.M. Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. American Journal of Respiratory and Critical Care Medicine 1997, 156:1738-1745.
26. Turner S.W. Genetic predictors of response to therapy in childhood asthma. Molecular Diagnosis & Therapy 2009, 13(2):127-135.
27. Israel E., Drazen J.M., Liggett S.B., Boushey H.A., Cherniack R.M., Chinchilli V.M., et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. American Journal of Respiratory and Critical Care Medicine 2000, 162:75-80.
28. Martinez F.D., Graves P.E., Baldini M., Solomon S., Erickson R. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. The Journal of Clinical Investigation 1997, 100:3184-3188.
29. Lee M.Y., Cheng S.N., Chen S.J., Huang H.L., Wang C.C., Fan H.C. Polymorphisms of the beta2-adrenergic receptor correlated to nocturnal asthma and the response of terbutaline nebulizer. Pediatrics and Neonatology 2011, 52:18-23.
30. Green S.A., Turki J., Innis M., Liggett S.B. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994, 33:9414-9419.
31. Hall I.P., Wheatley A., Wilding P., Liggett S.B. Association of Glu 27 beta 2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet 1995, 345(8959):1213-1214.
32. Reihsaus E., Innis M., MacIntyre N., Liggett S.B. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. American Journal of Respiratory Cell and Molecular Biology 1993, 8:334-339.
33. Taylor D.R., Drazen J.M., Herbison G.P., Yandava C.N., Hancox R.J., Town G.I. Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax 2000, 55:762-767.
34. Israel E., Chinchilli V.M., Ford J.G., Boushey H.A., Cherniack R., Craig T.J., et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004, 364:1505-1512.
35. Giubergia V., Gravina L.P., Castanos C., Chertkoff L., Grenoville M. Influence of beta2-adrenoceptor polymorphisms on the response to chronic use of albuterol in asthmatic children. Pediatric Pulmonology 2008, 43:421-425.
36. Carroll C.L., Sala K.A., Zucker A.R., Schramm C.M. Beta-adrenergic receptor polymorphisms associated with length of ICU stay in pediatric status asthmaticus. Pediatr Pulmonol 2012 Mar, 47:233-239.
37. Carroll C.L., Sala K.A., Zucker A.R., Schramm C.M. β2-adrenergic receptor haplotype linked to intubation and mechanical ventilation in children with asthma. J Asthma 2012, 49:563-568.
38. Turner S.W., Khoo S.K., Laing I.A., Palmer L.J., Gibson N.A., Rye P., Landau L.I., Goldblatt J., Le Souëf P.N. beta2 adrenoceptor Arg16Gly polymorphism, airway responsiveness, lung function and asthma in infants and children. Clin Exp Allergy 2004 Jul, 34. 1043-8g; 49(6):563-8.
39. Bleecker E.R., Postma D.S., Lawrance R.M., Meyers D.A., Ambrose H.J., Goldman M. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007 Dec 22, 370:2118-2125.
40. Bleecker E.R., Nelson H.S., Kraft M., Corren J., Meyers D.A., Yancey S.W., Anderson W.H., Emmett A.H., Ortega H.G. Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am J Respir Crit Care Med 2010 Apr 1, 181:676-687.